Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B Warren

Showing results (681-690 of 910) with videos related to

Pageof 91
Sort By:
American Journal of Perinatology|May 26, 2022
Video-Assisted Informed Consent in a Clinical Trial of Resuscitation of Extremely Preterm Infants: Lessons LearnedNamrita J Odackal, Catherine G Caruso, Melissa Klitzman, et al.
The Lancet. Rheumatology|January 22, 2024
Safety and efficacy of mirikizumab versus secukinumab and placebo in the treatment of moderate-to-severe plaque psoriasis (OASIS-2): a phase 3, multicentre, randomised, double-blind studyKim Papp, Richard B Warren, Lawrence Green, et al.
Dermatology and Therapy|September 16, 2024
Complete Skin Clearance is Associated with the Greatest Benefits to Health-Related Quality of Life and Perceived Symptoms for Patients with PsoriasisMatthias Augustin, Alice B Gottlieb, Mark Lebwohl, et al.
The British Journal of Dermatology|May 4, 2026
Serious infection risk with systemic treatments for psoriasis: A cohort study from the British Association of Dermatologists Biologic Interventions Register (BADBIR)Heber Rew Bright Bright, Catherine H Smith, Philip Laws, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|June 18, 2026
Prognostic prediction models for psoriatic arthritis in psoriasis: A systematic reviewFatimah Khoda, Yasmin Khan, William W Y Haw, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|October 22, 2019
Risk of major cardiovascular events in patients with psoriasis receiving biologic therapies: a prospective cohort studyW Rungapiromnan, K J Mason, M Lunt, et al.
The British Journal of Dermatology|March 4, 2020
Drug survival of adalimumab, ustekinumab and secukinumab in patients with psoriasis: a prospective cohort study from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR)Z Z N Yiu, K J Mason, P J Hampton, et al.
Dermatology and Therapy|October 8, 2025
Bimekizumab Efficacy in Psoriasis by Subgroups: Post Hoc Analysis of Phase 3/3b Clinical TrialsBruce Strober, Wolf-Henning Boehncke, James G Krueger, et al.
Lancet (London, England)|December 26, 2016
An intensified dosing schedule of subcutaneous methotrexate in patients with moderate to severe plaque-type psoriasis (METOP): a 52 week, multicentre, randomised, double-blind, placebo-controlled, phase 3 trialRichard B Warren, Ulrich Mrowietz, Ralph von Kiedrowski, et al.
The Journal of Investigative Dermatology|February 8, 2008
Genetic variation in efflux transporters influences outcome to methotrexate therapy in patients with psoriasisRichard B Warren, Rhodri L L Smith, Emanuela Campalani, et al.
Pageof 91

Showing results (681-690 of 910) with videos related to

Sort By:
Pageof 91
American Journal of Perinatology|May 26, 2022
Video-Assisted Informed Consent in a Clinical Trial of Resuscitation of Extremely Preterm Infants: Lessons LearnedNamrita J Odackal, Catherine G Caruso, Melissa Klitzman, et al.
The Lancet. Rheumatology|January 22, 2024
Safety and efficacy of mirikizumab versus secukinumab and placebo in the treatment of moderate-to-severe plaque psoriasis (OASIS-2): a phase 3, multicentre, randomised, double-blind studyKim Papp, Richard B Warren, Lawrence Green, et al.
Dermatology and Therapy|September 16, 2024
Complete Skin Clearance is Associated with the Greatest Benefits to Health-Related Quality of Life and Perceived Symptoms for Patients with PsoriasisMatthias Augustin, Alice B Gottlieb, Mark Lebwohl, et al.
The British Journal of Dermatology|May 4, 2026
Serious infection risk with systemic treatments for psoriasis: A cohort study from the British Association of Dermatologists Biologic Interventions Register (BADBIR)Heber Rew Bright Bright, Catherine H Smith, Philip Laws, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|June 18, 2026
Prognostic prediction models for psoriatic arthritis in psoriasis: A systematic reviewFatimah Khoda, Yasmin Khan, William W Y Haw, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|October 22, 2019
Risk of major cardiovascular events in patients with psoriasis receiving biologic therapies: a prospective cohort studyW Rungapiromnan, K J Mason, M Lunt, et al.
The British Journal of Dermatology|March 4, 2020
Drug survival of adalimumab, ustekinumab and secukinumab in patients with psoriasis: a prospective cohort study from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR)Z Z N Yiu, K J Mason, P J Hampton, et al.
Dermatology and Therapy|October 8, 2025
Bimekizumab Efficacy in Psoriasis by Subgroups: Post Hoc Analysis of Phase 3/3b Clinical TrialsBruce Strober, Wolf-Henning Boehncke, James G Krueger, et al.
Lancet (London, England)|December 26, 2016
An intensified dosing schedule of subcutaneous methotrexate in patients with moderate to severe plaque-type psoriasis (METOP): a 52 week, multicentre, randomised, double-blind, placebo-controlled, phase 3 trialRichard B Warren, Ulrich Mrowietz, Ralph von Kiedrowski, et al.
The Journal of Investigative Dermatology|February 8, 2008
Genetic variation in efflux transporters influences outcome to methotrexate therapy in patients with psoriasisRichard B Warren, Rhodri L L Smith, Emanuela Campalani, et al.
Pageof 91